mGem: AAV, from almost a virus to an awesome vector-or is it?

Area of Science:

• Biomedical research
• Gene therapy
• Viral vector technology

Background:

• Adeno-associated virus (AAV) vectors are pivotal in gene therapy, with seven approved for treating various genetic disorders.
• Despite clinical successes, current AAV vectors often necessitate high dosages for efficacy.
• High-dose AAV vector administration has been linked to serious adverse events and patient mortality.

Purpose of the Study:

• To critically evaluate the limitations of first-generation AAV vectors in gene therapy.
• To underscore the urgent need for developing advanced, safer AAV vector generations.
• To guide future research towards more effective and secure gene therapy solutions.

Main Methods:

• Review of clinical data and published studies on AAV vector efficacy and safety.
• Analysis of dose-dependent adverse events associated with first-generation AAV therapies.
• Comparative assessment of current AAV vector technology against therapeutic requirements.

Main Results:

• First-generation AAV vectors demonstrate efficacy but require high doses, increasing safety concerns.
• Significant adverse events and fatalities have been reported in patients receiving high-dose AAV treatments.
• The suboptimal nature of current AAV vectors necessitates a reevaluation of their use.

Conclusions:

• There is a critical need to address the dose-limiting toxicities of current AAV gene therapies.
• Advancing AAV vector technology is essential to enhance safety and broaden therapeutic applications.
• Future research should focus on engineering next-generation AAV vectors with improved safety profiles and efficacy.